D.E. Shaw & Co
EBACU

D.E. Shaw & Co’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

D.E. Shaw & Co’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68,721
Closed -$686K – 5420
2021
Q2 		$686K Buy
68,721
+35,388
+106% +$354K ﹤0.01% 3846
2021
Q1 		$335K Buy
+33,333
New +$333K ﹤0.01% 3666

Other funds holding EBACU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

D.E. Shaw & Co's EBACU Position: Q3 2021 in Review

D.E. Shaw & Co sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 68,721 shares — an estimated $686K sold.

D.E. Shaw & Co first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $686K in Q2 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

  • D.E. Shaw & Co reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 68,721 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $686K.
  • D.E. Shaw & Co first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's European Biotech Acquisition Corp. Units position peaked at $686K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.